Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial

Few standard treatment options are available for patients with metastatic sarcomas. We did this trial to evaluate the efficacy, safety, and changes in the tumour microenvironment for durvalumab, an anti-PD-L1 drug, and tremelimumab, an anti-CTLA-4 drug, across multiple sarcoma subtypes. In this sing...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2022-09, Vol.23 (9), p.1156-1166
Hauptverfasser:	Somaiah, Neeta, Conley, Anthony P, Parra, Edwin Roger, Lin, Heather, Amini, Behrang, Solis Soto, Luisa, Salazar, Ruth, Barreto, Carmelia, Chen, Honglei, Gite, Swati, Haymaker, Cara, Nassif, Elise F, Bernatchez, Chantale, Mitra, Akash, Livingston, John Andrew, Ravi, Vinod, Araujo, Dejka M, Benjamin, Robert, Patel, Shreyaskumar, Zarzour, Maria A, Sabir, Sharjeel, Lazar, Alexander J, Wang, Wei-Lien, Daw, Najat C, Zhou, Xiao, Roland, Christina L, Cooper, Zachary A, Rodriguez-Canales, Jaime, Futreal, Andrew, Soria, Jean-Charles, Wistuba, Ignacio I, Hwu, Patrick
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomarkers Bone cancer Bone Neoplasms - drug therapy Cancer therapies Clinical trials Colitis Creatinine CTLA-4 protein Cytotoxicity Disease Drug dosages Humans Immunotherapy Intravenous administration Liposarcoma Medical prognosis Metastases Metastasis Microenvironments Monoclonal antibodies Osteosarcoma Osteosarcoma - drug therapy Patients PD-L1 protein Pneumonia Pneumonitis Radiation therapy Response rates Sarcoma Sarcoma, Alveolar Soft Part - drug therapy Smooth muscle Soft Tissue Neoplasms - pathology Survival Synovial sarcoma Targeted cancer therapy Tumor Microenvironment Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!